introduction
For patients with cancer, and especially those with advanced and incurable cancer, adequate relief of pain is a central goal of care [1, 2] . Indeed, adequate relief of cancer pain is considered to be a human right by many organizations of health care professionals [3] [4] [5] [6] [7] [8] [9] [10] , but is not yet enshrined in human right conventions. This right implies duties; the duties of clinicians to assess pain and to treat it in accordance with the best of contemporaneous practices (that prevailing resources will enable), and that of governments and healthcare regulatory authorities to ensure that patients can access the medications needed to relieve pain.
There is a fundamental need to ensure that opioid analgesics are available to the patients who need them and to prevent these medications from becoming a source of harm or abuse. Drug abuse is a significant global problem. Although most of the opioids abused on a worldwide scale are obtained from illicit channels [11] , a proportion are prescription medications that have been diverted through fraud, theft, forged prescriptions, illegal pharmacies [11, 12] , and via unscrupulous health professionals [13] or poor clinical practice. These considerations demand that the parties involved in the legal manufacture, distribution, prescription and dispensing of opioid medications for medical purposes be mindful of their substantial abuse potential.
Ideally, international and local regulations of opioid manufacture, distribution, storage prescription, and dispensing should aim to maintain a balance between good patient care and diversion prevention. Preventing drug abuse is important, but it should not hinder patients' ability to receive the care they need and deserve. This is the approach of the World Health Organization (WHO) and the International Narcotics Control Board (INCB) [11, [14] [15] [16] [17] . Both recommend that opioids should be available for all patients with moderate to severe pain at hospital and community levels, and that physicians should be able to prescribe opioids according to the individual needs of each patient.
Opioid analgesics are critical to the effective relief of cancer pain. Effective treatment is predicated on sound assessments, individually tailored analgesic therapy, and the availability and accessibility of the required medications. In some countries, pain relief is hindered by the lack of availability or barriers to the accessibility of opioid analgesics. In many countries, excessively zealous drug controllers or policy makers, or poorly considered laws and regulations to restrict the diversion of medicinal opioids into illicit markets, profoundly interfere with the medical availability of opioids for the relief of pain. Often, the logistics of the treatment of pain with opioids is so burdensome or complex for physicians, nurses, and pharmacists as to be a major disincentive to the use of opioids in the treatment of pain.
This burden is compounded for patients, their families, and carers, who in many situations must cajole doctors, chase after permits, wait excessively in inconveniently located pharmacies, and return for frequent refills of prescriptions or any correction on a prescription that may not have been written with adequate attention to required details. In some countries, the degree of legal intimidation is such that fear of criminal prosecution contributes to deliberate under-treatment by clinicians to avoid risk of persecution or prosecution.
The problem of over-regulation has been highlighted by the INCB [15, 16, 18, 19] , the WHO [14, 20] , the Council of Europe [21] , and by Human Right Watch [3] . The consequences for health care professionals, patients, and their families are manifold and profound. Excessive regulatory restrictions make it nearly impossible for many patients to achieve relief of moderate and severe cancer pain that undermines their own quality of life and that of their family and carers.
A research initiative by WHO found that, in 2010, countries corresponding to 66% of the world population had virtually no consumption of strong opioids, 10% very low, 3% low, and 4% moderate. In fact, only 7.5% of the world's population resides in countries considered to have adequate consumption levels. In addition, the level of adequacy of access for a country has been shown to highly correlate with its Human Development Index (R 2 = 0.7583) [22] . In 2006, the European Society for Medical Oncology (ESMO) launched a campaign to improve the availability and accessibility of opioids for the management of cancer pain [23] . Partnering with the European Association for Palliative Care (EAPC), they produced in 2010 the first comprehensive survey of the formulary availability and cost of opioid medications in Europe and of the regulatory barriers that were possibly impeding access for cancer patients in need [24] . This study provided graphic evidence of the widespread problems that existed in much of Eastern Europe and the Baltic states and helped provide substrate data for intervention programs that are currently underway to address these shortcomings.
The countries of Africa, Asia, the Middle East, Latin America and the Caribbean, and the states of India are diverse with a wide range in the level of social and economic developments ranging from extreme wealth to extreme deprivation. This variability is reflected in the available data regarding the level of development of palliative care services and the degree to which they are integrated into the health care sector, and in per capita opioid consumption data [25] . To date, there have been no systematic studies to evaluate the availability and accessibility of opioids for the management of cancer pain or to evaluate the regulatory barriers that impede patient access to opioids for the relief of cancer pain.
conceptualization and development of the project As a follow up to the successful project to evaluate the availability and accessibility of opioids and regulatory barriers in Europe, ESMO and EAPC undertook to expand their research to those parts of the world where data were lacking regarding of these aspects of care. Given that good data were available regarding North America, Australia, and New Zealand, the identified geographic areas with inadequate data included Africa, Asia, and the Middle East, Latin America and the Caribbean, and the states of India. (The Indian states were surveyed separately because of their large populations and the complexity of the situation, which is different for each state.) The total population of these areas constitutes more than 5.7 billion people.
In view of the global scope of this project ESMO and EAPC invited three other important international organizations which have demonstrated pre-existing activity and commitment to these issues on a global scale to evaluate these issues. ESMO and EAPC together with the three other partners: the Union for International Cancer Control (UICC), the Pain and Policies Study Group (PPSG) of the University of Wisconsin, and the WHO constitute the five coordinating partners for this project. Within ESMO, the study activities were coordinated between the ESMO Executive Board, the Palliative Care Working Group, and the Emerging Countries Committee.
The aims of this study were to evaluate the formulary availability and cost to the consumer of the seven opioid formulations that have been deemed essential by the WHO and the International Association for Hospice and Palliative Care (IAHPC). In addition, the study aimed to evaluate the actual availability of these medicines for patients and the regulatory barriers that impede accessibility. A credible and comprehensive data set is essential for identifying shortcomings in the formulary and the actual availability, excessive costs to the consumer, and excessive regulatory barriers.
The adequacy of formulary availability was evaluated relative to the IAHPC list of essential medicines for palliative care and the WHO Model List of Essential Medicines, 17th Edition, [26] which was current at the start of this project. In 2007, the IAHPC developed an expert-generated essential medicines list for palliative care based on criteria of efficacy and safety. This list of recommendations, published in 2007 [27] [28] [29] [30] , is endorsed by the WHO Cancer Control Program [2] . The IAHPC lists all the formulations on the WHO Model List of Essential Medicines, 17th Edition, along with three others: transdermal fentanyl, oral methadone, and oral immediate release oxycodone (Table 1) . Over-regulation was evaluated according to the principles derived from the WHO guidelines for the assessment of national opioid policies and regulations [14, 20] .
This dataset provides a valuable foundation for global, regional, and national policy initiatives in individual countries that wish to take the right steps to truly improve the availability and accessibility of opioids for the management of cancer pain.
The five coordinating partner organizations have a shared responsibility for survey design, identification of collaborating partner organizations, identification of credible field reporters, data collection, and analysis. To ensure the widest possible coverage of the collection of data by field reporters, the coordinating partners invited the collaboration from palliative care and oncology organizations working in these regions. Seventeen organizations agreed to be 'collaborating partners' ( Table 2 ). The key roles for the collaborating partner organizations were in the identification of field reporters, encouraging compliance with data submission requirements and deadlines, and in the process of open peer review of the preliminary data.
methodology
The survey tool was based on the questionnaire developed and implemented in a study of opioid availability and accessibility in Europe [24] . The European questionnaire was modified by the coordinating partner organizations to collect additional data regarding the inclusion of opioids in a national essential medicines list, the presence or absence of a national palliative care association, cultural or social barriers to the use of opioids, changes in opioid regulation over the last 5 years, the actual availability of opioids to a patient holding a valid prescription, and the accessibility of sites able to dispense opioids for the management of cancer pain.
The survey was developed in English and was translated into Spanish and French. English and Spanish versions of the survey were prepared in a Form Master 2008 platform for electronic data collection via the EAPC website. The French version was distributed in electronic form by email and the data was manually entered into the online EAPC survey collection tool.
Data submitted by the two or more field reporters from each country/state were crosschecked by the Principle Investigator Nathan Cherny. When discrepancies between reporters were identified, clarifications were requested. When discrepancies persisted, priority was given to the response provided by the most highly credentialed reporter and where supportive data were presented. The principle investigator tabulated and graphically presented the data in the same format used in the European Survey.
A preliminary report of the findings was presented at the ESMO Congress in Vienna in September 2012. Between November 2012 and January 2013, the preliminary data was posted on the websites of ESMO, EAPC, and the PPSG. Invitations were sent to all members of the coordinating and collaborating partner organizations to review the data and to submit any corrections or amendments. Amendments were collated, crosschecked, and incorporated into the final report that was completed in May 2013.
results
One hundred and fifty-six complete reports were submitted from 104 countries and states (Table 3a and b). This figure represents 67% of the target countries and states. On a population basis, the dataset is relevant to 5.03 billion people, which represent 87.3% of the target population consisting of 5.76 billion people. In the open peer review process after presentation of the preliminary data, feedback was submitted by 49 persons via ESMO and EAPC, and by an additional 10 through the PPSG. Of these, 18 confirmed the veracity of the report for their country or state, and the remainder suggested corrections.
The specific findings relative to each region are presented in the subsequent papers in this supplement of Annals of Oncology.
disclaimers
The information presented in this survey was derived from practicing clinicians working in the field of palliative and/or cancer care and not from state authorities or statutory bodies. In circumstances in which the reporting physicians were unsure of a regulation or formulary issue they were requested to consult with regulatory authorities. The accuracy of the data is dependent on the accuracy of field reporters and their due diligence of verification of facts and regulations with any relevant authority. Field reporters were nominated on the basis of recognized involvement in practice and, in many cases, in leadership of cancer pain management in their country or state. We have no information regarding the extent to which field reporters verified their reporting. Although the methodology incorporated is designed to minimize error, including multiple reporters and crosschecks between reporters, this was not possible for 40 countries and most of the Indian states where submissions were received by a single reporter only. The study leadership considers the relatively small number of corrections submitted after the 60-day open peer review process as an indirect indicator of the integrity of the collated dataset.
The degree to which one specific regulatory restriction on opioid accessibility actually reduces patient access is variable and is influenced by specific procedural requirements and logistic arrangements. The authors also acknowledge that other documented factors besides the regulatory issues highlighted in this report may contribute to the under-treatment of cancer pain. These include the attitudes of patients and their families towards opioid medications, the knowledge and attitudes of the prescriber with respect to opioid use and the management of moderate and severe pain, and the availability and accessibility of other modalities for the treatment of cancer pain, such as radiotherapy.
discussion
Any national program for the relief of cancer pain must ensure both the availability of opioid medications and a regulatory environment that does not impede accessibility of opioids to patients with medical need. Addressing these issues requires a broad strategy involving policy reform, securing supply, cooperation of regulatory authorities, education of providers and consumers, and the development of a culture, emphasizing the importance of palliative care and pain relief. The data that have been collected and collated in this international collaboration provide valuable insights into common barriers to adequate pain management. This dataset should be used by governments and stakeholders in the fields of palliative care and cancer management as the basis for regulatory and policy reforms and to initiate essential measures to correct these shortcomings.
This international collaboration is the largest and most comprehensive that has ever been undertaken in the study of opioid availability and accessibility. It involved an unprecedented collection of resources and organizations cooperating together to derive a dataset that is relevant to more than two-thirds of the population of the world. It provides a graphic overview of the extent of the problem in the counties under evaluation that is unparalleled in its scope and detail. The study demonstrated the power of a shared commitment to the importance of pain relief for cancer patients, effective united leadership, highly skilled administrative support, and a strategic research agenda.
Major international efforts are underway to address the pandemic lack of availability and accessibility of opioids for the benefit of cancer patients (and other patients) in pain that affects the majority of the emerging economies and the developing world. The authors applaud recent progress on the global stage through inclusion of a specific target on access to essential medicines for cancer and other non-communicable diseases (NCDs) in the WHO Global NCD Action Plan 2013-2020. In addition, the WHO plan includes a specific indicator on morphine consumption in the associated Global Monitoring Framework (http://www.who.int/nmh/en/). Clearly, factors such as economic and social development are contributory; however, pilot projects in Uganda and Vietnam have demonstrated robustly that economic development is not an insurmountable barrier to the routine provision of pain medication for cancer patients suffering with severe pain.
The Global Opioid Policy Initiative (GOPI) members are partnering with other key civil society and intergovernmental agency players in the global efforts that are underway to improve accessibility to opioids for patients with cancer pain. The EAPC, the WHO, and Help the Hospices are key partners in the Access to Opioid Medication in Europe (ATOME) project (www. atome-project.eu). The ATOME project is a multiyear collaborative project involving 10 organizations to improve access to opioids across Europe by identifying and removing barriers that prevent people from accessing medicines that could improve end-of-life care, to alleviate debilitating pain, and to treat heroin dependence. It focuses on 12 target countries: Bulgaria, Cyprus, Estonia, Greece, Hungary, Latvia, Lithuania, Poland, Serbia, Slovakia, Slovenia, and Turkey. Based on individual country assessments, ATOME plans to formulate and disseminate tailor-made recommendations to each country for improving the accessibility, availability, and affordability of controlled medicines, and to disseminate these to governments, health care professionals, other key decision-making bodies, as well as to the general public. Early outputs of this initiative include the revision of the WHO publication 'Ensuring balance in national policies on controlled substances: guidance for the availability and accessibility of controlled medicines' [31] . This revised policy guide has been published in English and 14 other languages.
The 'Global Access to Pain Relief Initiative' (GAPRI) is another major international effort led by the UICC (www.uicc. org/programmes/gapri). This ambitious collaborative project aims to contribute to the World Cancer Declaration target of universal access to essential pain medications by the year 2020. GAPRI will achieve this through synergies between civil society organizations in the field of global and regional advocacy that include both public health and regulatory bodies, national capacity building through workshops, and country-based projects supported by UICC member organizations and partners, in order to embed pain and palliative care services into comprehensive approaches to cancer control. For example, GAPRI is partnering with The Pain and Policy Studies Group at the University of Wisconsin to support and train clinical leaders in tandem with regulatory representatives from the same country through an International Pain Policy Fellowship Program [32] . The graduates of these programs constitute an important part of the local leadership needed to champion the changes identified by this research.
Further, the American Cancer Society's 'Treat the Pain' campaign is implementing projects in Nigeria, Kenya, Uganda, India, and Haiti that are providing 2.8 million additional days of pain treatment.
In These international efforts are paying dividends. Through the process of advocacy, education, regulatory reform, and the engagement of suppliers, meaningful progress has been documented in many countries, including Romania, Hungary, the Czech Republic, Serbia, Armenia, Georgia, Columbia, Guatemala, Uganda, Kenya, Vietnam, and most recently, the Ukraine [33] [34] [35] [36] [37] [38] [39] [40] . This progress is incremental but real, and it exemplifies the potential for reform through concerted and sustained efforts [32] .
The data provided by the GOPI highlight, on a country-bycountry basis, issues in formulary inadequacy, problems with cost to consumer and actual availability of medication, and the extent of regulatory barriers that may be impeding accessibility of opioids to patients in need. Beyond the publication of the survey results, the data will be incorporated in targeted advocacy efforts across the membership of the international collaborating partners to achieve a worldwide outreach, aimed at sensitizing key decision-making bodies about the urgent need for policy reform and action at the country level.
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